265 related articles for article (PubMed ID: 31332341)
1. Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy.
Moreno AM; Palmer N; Alemán F; Chen G; Pla A; Jiang N; Leong Chew W; Law M; Mali P
Nat Biomed Eng; 2019 Oct; 3(10):806-816. PubMed ID: 31332341
[TBL] [Abstract][Full Text] [Related]
2. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.
Moreno AM; Fu X; Zhu J; Katrekar D; Shih YV; Marlett J; Cabotaje J; Tat J; Naughton J; Lisowski L; Varghese S; Zhang K; Mali P
Mol Ther; 2018 Jul; 26(7):1818-1827. PubMed ID: 29754775
[TBL] [Abstract][Full Text] [Related]
3. A multifunctional AAV-CRISPR-Cas9 and its host response.
Chew WL; Tabebordbar M; Cheng JK; Mali P; Wu EY; Ng AH; Zhu K; Wagers AJ; Church GM
Nat Methods; 2016 Oct; 13(10):868-74. PubMed ID: 27595405
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
[TBL] [Abstract][Full Text] [Related]
5. Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for
Dudek AM; Porteus MH
Front Immunol; 2021; 12():660302. PubMed ID: 34122418
[TBL] [Abstract][Full Text] [Related]
6. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.
Zhu J; Huang X; Yang Y
J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448
[TBL] [Abstract][Full Text] [Related]
7. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies.
Li Y; Li J; Liu Y; Shi Z; Liu H; Wei Y; Yang L
Gene Ther; 2019 Jun; 26(6):264-276. PubMed ID: 31110296
[TBL] [Abstract][Full Text] [Related]
8. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.
Tse LV; Klinc KA; Madigan VJ; Castellanos Rivera RM; Wells LF; Havlik LP; Smith JK; Agbandje-McKenna M; Asokan A
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4812-E4821. PubMed ID: 28559317
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
[TBL] [Abstract][Full Text] [Related]
11. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
12. Standard screening methods underreport AAV-mediated transduction and gene editing.
Lang JF; Toulmin SA; Brida KL; Eisenlohr LC; Davidson BL
Nat Commun; 2019 Jul; 10(1):3415. PubMed ID: 31363095
[TBL] [Abstract][Full Text] [Related]
13. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
14. Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic.
Kennedy EM; Kornepati AVR; Mefferd AL; Marshall JB; Tsai K; Bogerd HP; Cullen BR
Methods; 2015 Dec; 91():82-86. PubMed ID: 26291065
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
16. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
[TBL] [Abstract][Full Text] [Related]
17. AAV Vectorization of DSB-mediated Gene Editing Technologies.
Moser RJ; Hirsch ML
Curr Gene Ther; 2016; 16(3):207-19. PubMed ID: 27280971
[TBL] [Abstract][Full Text] [Related]
18. Genome Editing of Murine Liver Hepatocytes by AAV Vector-Mediated Expression of Cas9 In Vivo.
Kashiwakura Y; Ohmori T
Methods Mol Biol; 2023; 2637():195-211. PubMed ID: 36773148
[TBL] [Abstract][Full Text] [Related]
19. Characterization of promoters for adeno-associated virus mediated efficient Cas9 activation in adult Cas9 knock-in murine cochleae.
Zhao X; Jin C; Dong T; Sun Z; Zheng X; Feng B; Cheng Z; Li X; Tao Y; Wu H
Hear Res; 2020 Sep; 394():107999. PubMed ID: 32611519
[TBL] [Abstract][Full Text] [Related]
20. A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency.
Tordo J; O'Leary C; Antunes ASLM; Palomar N; Aldrin-Kirk P; Basche M; Bennett A; D'Souza Z; Gleitz H; Godwin A; Holley RJ; Parker H; Liao AY; Rouse P; Youshani AS; Dridi L; Martins C; Levade T; Stacey KB; Davis DM; Dyer A; Clément N; Björklund T; Ali RR; Agbandje-McKenna M; Rahim AA; Pshezhetsky A; Waddington SN; Linden RM; Bigger BW; Henckaerts E
Brain; 2018 Jul; 141(7):2014-2031. PubMed ID: 29788236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
